ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • synovial fluid and toll-like receptors
  • synovial fluid and total joint replacement
  • synovial fluid and transcription factor
  • synovial fluid and treatment
  • synovial fluid and tumor necrosis factor (TNF)
  • synovial fluid and ultrasound
  • synovial fluid and uric acid
  • synovial fluid and vasculogenesis
  • synovial fluid and WNT Signaling
  • Synovial Immune Biology
  • Synovial Immune Biology and epigenetics
  • Synovial Immune Biology and metabolism
  • Synovial Immune Biology and rheumatoid arthritis
  • Synovial Immune Biology and rheumatoid arthritis (RA)
  • Synovial Immune Biology and ultrasound
  • synovial tissue
  • Synovitis
  • synovitis and biomarkers
  • synovitis and pain
  • synovitis and synovium
  • synovitis and systemic sclerosis
  • synovitis and T cells
  • synovitis and tendonitis/bursitis
  • synovitis and therapy
  • synovitis and tofacitinib
  • synovitis and tolerance
  • synovitis and transforming growth factor
  • synovitis and treatment
  • synovitis and tuberculosis
  • synovitis and tumor necrosis factor (TNF)
  • synovitis and ultrasonography
  • synovitis and ultrasound
  • synovitis and uric acid
  • synovium
  • synovium and adhesion molecules
  • synovium and arthritis
  • synovium and Cell Migration
  • synovium and rituximab
  • synovium and severity
  • synovium and signal transduction
  • synovium and synovial cells
  • synovium and synovitis
  • synovium and tocilizumab
  • synovium and toll-like receptors
  • synovium and transcription factor
  • synovium and transcriptional regulation
  • synovium and transforming growth factor
  • synovium and treatment
  • synovium and tumor necrosis factor (TNF)
  • synovium and ultrasonography
  • synovium and ultrasound
  • synthetase syndrome
  • synthetase syndrome and systemic sclerosis
  • synthetase syndrome and transplantation
  • synthetase syndrome and treatment
  • systematic literature review
  • systematic literature review and assessment
  • systematic review
  • Systematic Review and antibodies
  • Systematic review and rheumatoid arthritis (RA)
  • systemic autoimmune diseases
  • systemic illness
  • systemic illness and systemic sclerosis
  • systemic illness and treatment
  • systemic illness and uveitis
  • Systemic Inflammatory
  • Systemic Inflammatory and rheumatoid arthritis (RA)
  • Systemic JIA
  • Systemic JIA and adult-onset Still's disease
  • Systemic JIA and biomarkers
  • Systemic JIA and canakinumab
  • Systemic JIA and Clinical Response
  • Systemic JIA and drug therapy
  • Systemic JIA and genetics
  • Systemic JIA and genomics
  • Systemic JIA and glucocorticoids
  • Systemic JIA and interleukins (IL)
  • Systemic JIA and juvenile idiopathic arthritis (JIA)
  • Systemic JIA and macrophage activation syndrome
  • Systemic JIA and monocytes
  • Systemic JIA and mouse model
  • Systemic JIA and risk
  • Systemic JIA and rituximab
  • Systemic JIA and tocilizumab
  • systemic juvenile idiopathic arthritis
  • Systemic Lupus Erythematosus
  • Systemic lupus erythematosus (SLE)
  • systemic lupus erythematosus (SLE) and African-Americans
  • systemic lupus erythematosus (SLE) and biomarkers
  • systemic lupus erythematosus (SLE) and biopsy
  • systemic lupus erythematosus (SLE) and classification criteria
  • systemic lupus erythematosus (SLE) and clinical practice
  • systemic lupus erythematosus (SLE) and clinical trials
  • systemic lupus erythematosus (SLE) and cognitive dysfunction
  • systemic lupus erythematosus (SLE) and cytokines
  • systemic lupus erythematosus (SLE) and diagnosis
  • systemic lupus erythematosus (SLE) and Diagnostic Tests
  • systemic lupus erythematosus (SLE) and Disease Activity
  • systemic lupus erythematosus (SLE) and DNA Methylation
  • systemic lupus erythematosus (SLE) and doctor-patient relationship
  • systemic lupus erythematosus (SLE) and economics
  • systemic lupus erythematosus (SLE) and exercise
  • systemic lupus erythematosus (SLE) and fatigue
  • systemic lupus erythematosus (SLE) and flow cytometry
  • systemic lupus erythematosus (SLE) and hydroxychloroquine
  • systemic lupus erythematosus (SLE) and IL-23
  • systemic lupus erythematosus (SLE) and interferons
  • systemic lupus erythematosus (SLE) and level of knowledge
  • systemic lupus erythematosus (SLE) and opioids
  • systemic lupus erythematosus (SLE) and outcomes
  • systemic lupus erythematosus (SLE) and patient questionnaires
  • systemic lupus erythematosus (SLE) and pediatric rheumatology
  • systemic lupus erythematosus (SLE) and prognostic factors
  • systemic lupus erythematosus (SLE) and quality of life
  • systemic lupus erythematosus (SLE) and renal disease
  • systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
  • systemic lupus erythematosus (SLE) and slicc
  • systemic lupus erythematosus (SLE) and systemic sclerosis
  • systemic lupus erythematosus (SLE) and T cells
  • systemic lupus erythematosus (SLE) and tacrolimus
  • systemic lupus erythematosus (SLE) and takayasu arteritis
  • systemic lupus erythematosus (SLE) and technology
  • systemic lupus erythematosus (SLE) and therapeutic targeting
  • systemic lupus erythematosus (SLE) and therapy
  • Systemic lupus erythematosus (SLE) and thrombocytopenia
  • systemic lupus erythematosus (SLE) and thrombosis
  • systemic lupus erythematosus (SLE) and tobacco use
  • systemic lupus erythematosus (SLE) and tolerance
  • systemic lupus erythematosus (SLE) and toll-like receptors
  • systemic lupus erythematosus (SLE) and total joint replacement
  • systemic lupus erythematosus (SLE) and transcription factor
  • systemic lupus erythematosus (SLE) and transforming growth factor
  • systemic lupus erythematosus (SLE) and transplantation
  • systemic lupus erythematosus (SLE) and treatment
  • systemic lupus erythematosus (SLE) and treatment options
  • systemic lupus erythematosus (SLE) and tumor necrosis factor (TNF)
  • systemic lupus erythematosus (SLE) and ulcers
  • systemic lupus erythematosus (SLE) and ultrasonography
  • systemic lupus erythematosus (SLE) and ultrasound
  • systemic lupus erythematosus (SLE) and uric acid
  • systemic lupus erythematosus (SLE) and utilization review
  • systemic lupus erythematosus (SLE) and vaccines
  • systemic lupus erythematosus (SLE) and vasculitis
  • systemic lupus erythematosus (SLE) and vasculogenesis
  • systemic lupus erythematosus (SLE) and viruses
  • systemic lupus erythematosus (SLE) and vitamins
  • Systemic lupus erythematosus (SLE) and weight loss
  • systemic lupus erythematosus (SLE) and well-being
  • systemic lupus erythematosus (SLE) and women's health
  • Systemic lupus erythematosus (SLE) and work
  • Systemic lupus erythematosus (SLE), Childhood-onset
  • Systemic Mastocytosis
  • systemic necrotizing vasculitis
  • Systemic rheumatic disease
  • Systemic sclerosis
  • systemic sclerosis and autoantibodies
  • systemic sclerosis and calcinosis
  • systemic sclerosis and cd163
  • systemic sclerosis and classification criteria
  • systemic sclerosis and clinical trials
  • systemic sclerosis and death
  • systemic sclerosis and education
  • systemic sclerosis and epigenetics
  • systemic sclerosis and gastrointestinal complications
  • systemic sclerosis and Health Care
  • systemic sclerosis and heart disease
  • systemic sclerosis and interstitial lung disease
  • systemic sclerosis and localized scleroderma
  • systemic sclerosis and outcome measures
  • systemic sclerosis and PAH
  • systemic sclerosis and pathogenesis
  • systemic sclerosis and Raynaud's phenomenon
  • systemic sclerosis and systemic vasculitides
  • systemic sclerosis and tacrolimus
  • systemic sclerosis and therapeutic targeting
  • Systemic sclerosis and therapy
  • systemic sclerosis and thrombosis
  • systemic sclerosis and thyroid
  • systemic sclerosis and tissue engineering
  • systemic sclerosis and tissue growth factor (TGF)
  • Systemic sclerosis and tobacco use
  • systemic sclerosis and tocilizumab
  • systemic sclerosis and tofacitinib
  • systemic sclerosis and tolerance
  • systemic sclerosis and toll-like receptors
  • systemic sclerosis and transcription factor
  • systemic sclerosis and transcriptional regulation
  • systemic sclerosis and transforming growth factor
  • systemic sclerosis and transplantation
  • systemic sclerosis and treatment
  • systemic sclerosis and treatment options
  • systemic sclerosis and tyrosine kinase inhibition
  • systemic sclerosis and ulcers
  • Systemic sclerosis and ultrasonography
  • systemic sclerosis and ultrasound
  • Systemic sclerosis and vaccines
  • systemic sclerosis and vasculitis
  • systemic sclerosis and vasculogenesis
  • systemic sclerosis and viruses
  • systemic sclerosis and vitamins
  • First |
  • « Previous Page
  • 57
  • 58
  • 59
  • 60
  • 61
  • [62]
  • 63
  • 64
  • 65
  • 66
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology